PRNB - Principia Biopharma Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
63.84
+2.92 (+4.79%)
At close: 4:00PM EDT

63.84 0.00 (0.00%)
After hours: 4:09PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close60.92
Open60.96
Bid63.58 x 800
Ask67.01 x 800
Day's Range59.56 - 64.43
52 Week Range25.35 - 75.65
Volume237,512
Avg. Volume326,909
Market Cap2.109B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.59
Earnings DateAug 03, 2020 - Aug 13, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est78.57
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Principia Announces Data Presentations of Rilzabrutinib in Patients with Immune Thrombocytopenia (ITP) at Two Upcoming Virtual Medical Meetings

    SOUTH SAN FRANCISCO, Calif., May 26, 2020 -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for.

  • GlobeNewswire

    Principia Biopharma Reports First Quarter 2020 Financial Results

    SOUTH SAN FRANCISCO, Calif., May 06, 2020 -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for.

  • GlobeNewswire

    Principia Biopharma to Present at the 2020 Bank of America Health Care Conference

    Principia is a late-stage biopharmaceutical company dedicated to bringing transformative therapies to patients with significant unmet medical needs in immune-mediated diseases. Through Principia’s proprietary Tailored Covalency® platform, our strategy is to build and advance a pipeline of best-in-class drug candidates with significant therapeutic benefits, limit unintended side effects, improve quality of life and over time modify the course of disease. Rilzabrutinib, a reversible covalent BTK inhibitor, is being evaluated in a global Phase 3 clinical trial in patients with pemphigus, a Phase 1/2 clinical trial in patients with immune thrombocytopenia (ITP), and the company plans to initiate a Phase 2 clinical trial in patients with IgG4-Related Diseases.

  • Were Hedge Funds Right About Principia Biopharma Inc. (PRNB)?
    Insider Monkey

    Were Hedge Funds Right About Principia Biopharma Inc. (PRNB)?

    We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]

  • Top Stock Picker Sees New Alignment With Covid-19
    Bloomberg

    Top Stock Picker Sees New Alignment With Covid-19

    (Bloomberg Opinion) -- Eddie Yoon took over the Fidelity Select Health Care Fund in 2008, just as the financial crisis ushered in the worst recession since the Great Depression. He outperformed health-care's benchmark during the ensuing 12 years when his fund quintupled to almost $7 billion. That record made him No. 1 among 20 peers managing at least $200 million with combined 1-to-5-year returns, according to data compiled by Bloomberg.He has never seen anything like the Covid-19 pandemic, an unprecedented disruption that, for the first time, he says, is aligning patients, health-care providers and payers, including insurers.The coronavirus has “fundamentally changed the way we think about the outlook,” said the 40-year-old Yoon earlier this month in a remotely arranged interview near Fidelity's Boston headquarters. “Big winners and losers are going to emerge, and that provides an enormous opportunity for folks like us that run active funds that really capitalize on the companies that are going to be successful in that new world.”Basel-based Roche Holding AG, Indianapolis-based Eli Lilly & Co., London-based AstraZeneca PLC and South San Francisco-based Principia Biopharma Inc. are “still are very big parts” of Fidelity Select Health Care. They appreciated 20%, 17%, 14% and 110%, respectively, during the past 12 months.Yoon said he relies on the “same investment framework that we've been using for over 10 years.” This means focusing simultaneously on free cash flow — how much money a business has to sustain its operations after paying for buildings, equipment and other capital expenditures — and the long-term growth rates of companies.“We construct a portfolio where we're trying to extract the most amount of return — income plus appreciation — for the least amount of risk,” Yoon said. “With the demand shock we're seeing in our economy as well as this public health-care crisis, things are changing rapidly, so when you are uncertain, you want more downside protection or more upside opportunity.”Fidelity Select Health Care almost tripled its weighting in Western European companies compared with the MSCI US Health Care Index during the past three years at the expense of U.S. companies whose underweighting increased to 19% from 10% versus the benchmark, according to data compiled by Bloomberg. “Coming into 2019, we were de-risking” as “a lot of growth stocks got very, very expensive,” said Yoon, who joined Fidelity after an initial stint at JPMorgan Asset Management starting in 2002, when he received a B.A. in business economics from Brown University.  “We actually narrowed the pharmaceuticals positioning in the fund, and I own more large pharma companies now than I have before.”Fidelity Select Health Care gained 9.3% during the past 12 months, outperforming the benchmark by 5.2% when the MSCI declined 4.1%. Most of the return came from the pharmaceutical companies he selected even when the fund held fewer of them than the benchmark, according to data compiled by Bloomberg.“My general philosophy is deliver a double-digit return for shareholders that will outperform the underlying benchmark and other asset classes that investors might want to put their capital into,” Yoon said. The fund returned 549% since he became its manager. Health care remains something of a haven during periods of market turbulence. When the S&P 500 index lost 12% last month, the shares of health-care companies lost only 3.8% when the comparable measures for the financial and energy industries declined 21% and 35%, respectively. During the last recession, between December 2007 and June 2009, health care retreated 25% when the S&P 500 decreased 35%, according to data compiled by Bloomberg.Yoon, who also oversees Fidelity's global health-care research, said “until we get to a way to find a health-care breakthrough — whether it be a therapeutic, a preventative medicine, helping people develop antibodies against the coronavirus or a vaccine — we're going to have to deal with this coronavirus as we think about the demand picture for the foreseeable future.”While Yoon dealt with the upheaval of the financial crisis in 2008 and 2009 and the disruption caused by the 2010 Affordable Care Act, which went into effect in 2013, “this time it's different,” he said.“The companies that we're trying to find that actually are impacted by this crisis are companies that are going to see a cyclical benefit where demand is going to rise because of the coronavirus and then stay high for longer because of something unique in their business model. Those are the companies we own and will hopefully own for a long time.”\-- With assistance from Shin Pei, Cara Slear and Chase Lynch.This column does not necessarily reflect the opinion of Bloomberg LP and its owners.Matthew A. Winkler is Co-founder of Bloomberg News (1990) and Editor-in-Chief Emeritus; Bloomberg Opinion Columnist since 2015; Co-founder of Bloomberg Business Journalism Diversity Program in 2017. During his 25 years as Editor-in-Chief, Bloomberg News was a three-time finalist and winner of the Pulitzer Prize for Explanatory Reporting and received numerous George Polk, Gerald Loeb, Overseas Press Club and Society of Professional Journalists and Editors (Sabew) awards.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • GlobeNewswire

    Principia Biopharma Reports Fourth Quarter and Full Year 2019 Financial Results

    SOUTH SAN FRANCISCO, Calif., March 10, 2020 -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for.

  • GlobeNewswire

    Principia to Present at 9th Annual SVB Leerink Global Healthcare Conference

    Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced that management will participate in the SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020, at 10:00 am EST at the Lotte New York Palace Hotel. Principia is a late-stage biopharmaceutical company dedicated to bringing transformative therapies to patients with significant unmet medical needs in immune-mediated diseases. Rilzabrutinib, a reversible covalent BTK inhibitor, is being evaluated in a Phase 3 clinical trial in patients with pemphigus -- an orphan autoimmune disease -- a Phase 2 clinical trial in patients with immune thrombocytopenia (ITP), and the company plans to initiate a Phase 2 clinical trial in patients with IgG4-related diseases.

  • GlobeNewswire

    Principia Announces Expansion of its BTK Franchise with PRN473 Topical

    Company expands focus on immune-mediated diseases and suspends FGFR program Company outlines anticipated key corporate milestones SOUTH SAN FRANCISCO, Calif.,.

  • GlobeNewswire

    Principia Announces Expanded Development Program to Broaden BTK Footprint in Immune-Mediated Diseases

    Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, today announced an expansion in the development of rilzabrutinib (PRN1008) into IgG4-Related Disease (RD). This clinical program broadens the company’s Bruton tyrosine kinase (BTK) therapeutic areas and supports the company’s commitment to innovate and solve high unmet needs.

  • Fear and loathing in Union Square: Upcoming biotech conference exposes industry dreams, issues
    American City Business Journals

    Fear and loathing in Union Square: Upcoming biotech conference exposes industry dreams, issues

    As lawmakers talk about drug price controls, drug developers are simply trying to find a place to stay during the J.P. Morgan Healthcare Conference for under $1,000 a night.

  • GlobeNewswire

    Principia Updates PRN1008 Pemphigus Clinical Program

    Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immune-mediated diseases, today announced updated anticipated timing for final results in its ongoing pivotal Phase 3 clinical trial of PRN1008 data in patients with pemphigus, as well as complete response rates from its Phase 2 Part B open-label trial.

  • Principia Biopharma Inc. (PRNB): Hedge Funds In Wait-and-See Mode
    Insider Monkey

    Principia Biopharma Inc. (PRNB): Hedge Funds In Wait-and-See Mode

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

  • Why Merck, Sanofi News Helped This Biotech Rocket 32% Over Three Days
    Investor's Business Daily

    Why Merck, Sanofi News Helped This Biotech Rocket 32% Over Three Days

    Principia Biopharma stock has rocketed 32% this week amid enthusiasm for its technology, BTK inhibition — highlighted by notable moves from pharmaceutical giants Merck and Sanofi.

  • Benzinga

    The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares

    The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics ...

  • GlobeNewswire

    Principia Presents Consistent Positive Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial

    Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced consistent positive data from an ongoing Phase 1/2 trial of its investigational treatment, PRN1008, in 31 highly treatment-resistant and refractory patients (median of six prior therapies) with immune thrombocytopenia (ITP). The data from the trial is being presented today by David Kuter, M.D., Director of Clinical Hematology at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School, at an oral scientific session of the 61st American Society of Hematology Annual Meeting (ASH).

  • GlobeNewswire

    Principia to Present at the Stifel Healthcare Conference 2019

    Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced that management will participate in the Stifel Healthcare Conference on Tuesday, November 19, 2019, at 11:30 am EST in the Garrison Room at the Lotte New York Palace Hotel. Principia is a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases.

  • GlobeNewswire

    Principia Biopharma Reports Third Quarter Financial Results

    SOUTH SAN FRANCISCO, Calif., Nov. 05, 2019 -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune.

  • Is Principia Biopharma Inc. (PRNB) A Good Stock To Buy?
    Insider Monkey

    Is Principia Biopharma Inc. (PRNB) A Good Stock To Buy?

    The Insider Monkey team has completed processing the quarterly 13F filings for the June quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]

  • American City Business Journals

    These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year

    While initial public offerings get most of the splash, public companies also are raking in cash with follow-on offerings. How long will the Wall Street spigot stay open?

  • Benzinga

    The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) Celgene Corporation (NASDAQ: CELG ) Eagle Pharmaceuticals ...

  • GlobeNewswire

    Principia Announces Pricing of Public Offering of Common Stock

    Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced the pricing of its underwritten public offering of 7,500,000 shares of its common stock at a price to the public of $28.00 per share. The gross proceeds to Principia from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by Principia, are expected to be $210 million. Principia has also granted the underwriters a 30-day option to purchase up to 1,125,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions.

  • GlobeNewswire

    Principia Announces Proposed Public Offering of Common Stock

    Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced that it has commenced an underwritten public offering of $125 million of its common stock. Principia also intends to grant the underwriters a 30-day option to purchase up to an additional $18,750,000 of the shares of common stock sold in the public offering. All of the shares are being offered by Principia.

  • GlobeNewswire

    Principia Announces Positive Preliminary Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial

    Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced positive preliminary data from an ongoing Phase 1/2 trial of its investigational treatment, PRN1008, in a highly treatment-resistant and refractory patient population (median of five prior therapies) with immune thrombocytopenia (ITP). Further updated data from the trial will be presented at an oral scientific session at the 61st American Society of Hematology Annual Meeting in December (ASH).

  • GlobeNewswire

    Principia Announces Positive Preliminary Data of PRN1008 from its Ongoing Phase 2 Part B Trial in Pemphigus

    SOUTH SAN FRANCISCO, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE) --  Principia Biopharma Inc. (PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced positive preliminary data from its Phase 2 pemphigus, open-label, trial. “As we are actively recruiting patients for the Phase 3 PEGASUS trial, I believe it is important to recognize that, between the Phase 2 Parts A and B of the pemphigus trial, we now have been able to observe consistent safety and efficacy data in approximately 40 pemphigus patients,” said Dr. Murrell, professor and Head of the Department of Dermatology at The St. George Hospital Clinic School, University of New South Wales in Sydney, Australia, who is the Principal Investigator of the PEGASUS Phase 3 trial.

  • Should Principia Biopharma (NASDAQ:PRNB) Be Disappointed With Their 13% Profit?
    Simply Wall St.

    Should Principia Biopharma (NASDAQ:PRNB) Be Disappointed With Their 13% Profit?

    These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But you can...